EN | TR
E-ISSN: 2147-2661
Allograft Reaction After Latanoprost use Following Penetrating Keratoplasty for Corneal Scarring due to Herpetic Keratitis
PDF
Cite
Share
Request
Case Report
VOLUME: 42 ISSUE: 2
P: 150-153
March 2012

Allograft Reaction After Latanoprost use Following Penetrating Keratoplasty for Corneal Scarring due to Herpetic Keratitis

Turk J Ophthalmol 2012;42(2):150-153
DOI: 10.4274/tjo.42.462200
Suphi Acar 1
Tahir Kansu Bozkurt 2
Ayşe Ebru Bahadır 3
Selda Aktay Kutan 4
1. Haydarpasa Numune Egitim Ve Arastirma Hastanesi, 2. Göz Klinigi, Istanbul, Türkiye
2. Gümüssuyu Asker Hastanesi, Göz Klinigi, Istanbul, Türkiye
3. Sakarya Hendek Devlet Hastanesi, Göz Klinigi, Sakarya, Türkiye
4. Karadeniz Eregli Devlet Hastanesi, Göz Klinigi, Zonguldak, Türkiye
No information available.
No information available
Received Date: 20.11.2010
Accepted Date: 03.08.2011
PDF
Cite
Share
Request

ABSTRACT

A 27-year-old male patient with a corneal scar secondary to herpetic keratitis in the right eye underwent penetrating keratoplasty (PK). At the 14th month of follow-up, latanoprost was started to treat high intraocular pressure which was refractory to treatment. On the 15th day of latanoprost use, allograft reaction (AR) developed. Insufficient clinical response despite intensive immunosuppressive therapy made us consider the possibility of recurrent herpetic keratouveitis secondary to steroid treatment. The dramatic reduction in the number of keratic precipitates with oral valacyclovir treatment confirmed this diagnosis. The graft remained clear 3 months after the AR treatment. Inflammation in eyes that had undergone PK jeopardizes the graft success by disrupting the immune privilege of anterior chamber. Considering the effects of prostaglandin analogues on blood-aqueous barrier, latanoprost use might have been related to allograft reaction in this case. Another remarkable characteristics of this case was the herpes simplex virus (HSV) reactivation secondary to AR therapy. For this reason, oral acyclovir prophylaxis together with AR therapy would improve graft success in cases with HSV history. (Turk J Ophthalmol 2012; 42: 150-3)

References

1Liesegang TJ, Melton LJ 3rd, Daly PJ, Ilstrup DM. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol. 1989;107:1155-9.
2Remeijer L, Doornenbal P, Geerards AJ, Rijneveld WA, Beekhuis WH. Newly acquired herpes simplex virus keratitis after penetrating keratoplasty. Ophthalmology. 1997;104:648-52.
3Thompson RW Jr, Price MO, Bowers PJ, Price FW Jr. Long-term graft survival after penetrating keratoplasty. Ophthalmology. 2003;110:1396-402.
4LLomholt JA, Baggesen K, Ehlers N. Recurrence and rejection rates following corneal transplantation for herpes simplex keratitis. Acta Ophthalmol. Scand 1995;73:29-32.
5Panda A, Vanathi M, Kumar A, Dash Y, Priya S. Corneal graft rejection. Surv Ophthalmol. 2007;52:375-96.
6The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. Arch Ophthalmol. 1992;110:1392-403.
7D'Amaro J, Volker-Dieben HJ, Kruit PJ, de Lange P, Schipper R. Influence of pretransplant sensitization on the survival of corneal allografts. Transplant Proc. 1991;23:368-72.
8Cobo LM, Coster DJ, Rice NS, Jones BR. Prognosis and management of corneal transplantation for herpetic keratitis. Arch Ophthalmol. 1980;98:1755-9.
9Ficker LA, Kirkness CM, Rice NS, Steele AD. The changing management and improved prognosis for corneal grafting in herpes simplex keratitis. Ophthalmology. 1989;96:1587-96.
10Williams KA, Roder D, Esterman A, Muehlberg SM, Coster DJ. Factors predictive of corneal graft survival. Report from the Australian Corneal Graft Registry. Ophthalmology. 1992;99:403-14.
11Shtein RM, Garcia DD, Musch DC, Elner VM. Herpes simplex virus keratitis: histopathologic inflammation and corneal allograft rejection. Ophthalmology. 2009;116:1301-5.
12Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmo.l 2008;53 Suppl1:S93-105.
13Moroi SE, Gottfredsdottir MS, Schteingart MT, et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology. 1999;106:1024-9.
14Lima MC, Paranhos A, Jr., Salim S, et al. Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost. J Glaucoma. 2000;9:317-21.
15Massry GG, Assil KK. Pilocarpine-associated allograft rejection in postkeratoplasty patients. Cornea. 1995;14:202-5.
16Dada T, Aggarwal A, Minudath KB, et al. Post-penetrating keratoplasty glaucoma. Indian J Ophthalmol. 2008;56:269-77.
17Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol. 1999;127:602-4.
18Ekatomatis P. Herpes simplex dendritic keratitis after treatment with latanoprost for primary open angle glaucoma. Br J Ophthalmol. 2001;85:1008-9.
19Kaufman HE, Varnell ED, Thompson HW. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am J Ophthalmol. 1999;127:531-6.
20Barney NP, Foster CS. A prospective randomized trial of oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Cornea. 1994;13:232-6.
21Akova YA, Onat M, Duman S. Efficacy of low-dose and long-term oral acyclovir therapy after penetrating keratoplasty for herpes simplex heratitis. Ocul Immunol Inflamm. 1999;7:51-60.
22van Rooij J, Rijneveld WJ, Remeijer L, et al. Effect of oral acyclovir after penetrating keratoplasty for herpetic keratitis: a placebo-controlled multicenter trial. Ophthalmology. 2003;110:1916-9.
Article is only available in PDF format. Show PDF
2024 ©️ Galenos Publishing House